HIV Disease Coverage Forecast and Market Analysis to 2024

  • ID: 4533538
  • Report
  • 479 pages
  • Datamonitor Healthcare
1 of 3
Disease Overview

The human immunodeficiency virus, or HIV, is a retrovirus that infects the cells of the immune system such as T lymphocytes, specifically cluster of differentiation-4+ T cells, dendritic cells, and macrophages. Infection leads to a progressive weakening of the immune system and ultimately results in acquired immunodeficiency syndrome (AIDS).

Market Snapshot
  • B/F/TAF will drive significant revenue growth due to its attractive combination of an INSTI and a preferred backbone.
  • TAF-based regimens are rapidly cannibalizing the share of TDF-based products due to superior renal and bone safety.
  • HIV prevalence is increasing in the analyzed markets as people are living longer on antiretroviral therapy.
  • Rapid uptake of TAF-based regimens in the US will protect Gilead’s revenues following TDF patent expiry.
  • B/F/TAF’s potency and clean tolerability profile will outcompete its rivals, restricting their uptake at launch.
Note: Product cover images may vary from those shown
2 of 3
FORECAST: HIV (Published on 22 December 2017)
OVERVIEW
EXECUTIVE SUMMARY
MARKET DYNAMICS
FORECAST AND FUTURE TRENDS
MARKET DEFINITION AND METHODOLOGY
PRIMARY RESEARCH METHODOLOGY
BIBLIOGRAPHY
PRODUCT PROFILE: ATRIPLA
PRODUCT PROFILE (LATE STAGE): B/F/TAF
PRODUCT PROFILE: COMPLERA
PRODUCT PROFILE (LATE STAGE): DOR/3TC/TDF
PRODUCT PROFILE: DESCOVY
PRODUCT PROFILE: GENVOYA
PRODUCT PROFILE: ISENTRESS
PRODUCT PROFILE: JULUCA
PRODUCT PROFILE: ODEFSEY
PRODUCT PROFILE: PREZISTA FRANCHISE
PRODUCT PROFILE: REYATAZ FRANCHISE
PRODUCT PROFILE: STRIBILD
PRODUCT PROFILE: SYMTUZA
PRODUCT PROFILE: TIVICAY
PRODUCT PROFILE (LATE STAGE): TIVICAY/EPIVIR
PRODUCT PROFILE: TRIUMEQ
PRODUCT PROFILE: TRUVADA
PRODUCT PROFILE (LATE STAGE): CABOTEGRAVIR/RILPIVIRINE
PRODUCT PROFILE (LATE STAGE): FOSTEMSAVIR

TREATMENT: HIV (Published on 13 April 2018)
OVERVIEW
PRIMARY RESEARCH METHODOLOGY
DISEASE DEFINITION AND DIAGNOSIS
PATIENT SEGMENTATION
CURRENT TREATMENT OPTIONS
TREATMENT GUIDELINES
PRESCRIBING TRENDS
UNMET NEEDS IN HIV
IMPACT OF GENERICS

EPIDEMIOLOGY: HIV (Published on 30 August 2017)
OVERVIEW
EXECUTIVE SUMMARY
DISEASE BACKGROUND
SOURCES AND METHODOLOGY
FORECAST: HIV
EPIDEMIOLOGIST INSIGHT
STRENGTHS AND LIMITATIONS
APPENDIX: ADDITIONAL SOURCES
BIBLIOGRAPHY

MARKETED DRUGS: HIV (Published on 22 December 2017)
OVERVIEW
EXECUTIVE SUMMARY
PRODUCT OVERVIEW
PRODUCT PROFILE: ATRIPLA
PRODUCT PROFILE: COMPLERA
PRODUCT PROFILE: DESCOVY
PRODUCT PROFILE: GENVOYA
PRODUCT PROFILE: ISENTRESS
PRODUCT PROFILE: JULUCA
PRODUCT PROFILE: ODEFSEY
PRODUCT PROFILE: PREZISTA FRANCHISE
PRODUCT PROFILE: REYATAZ FRANCHISE
PRODUCT PROFILE: STRIBILD
PRODUCT PROFILE: SYMTUZA
PRODUCT PROFILE: TIVICAY
PRODUCT PROFILE: TRIUMEQ
PRODUCT PROFILE: TRUVADA

PIPELINE: HIV (Published on 22 December 2017)
OVERVIEW
EXECUTIVE SUMMARY
CLINICAL PIPELINE OVERVIEW
PRODUCT PROFILE (LATE STAGE): B/F/TAF
PRODUCT PROFILE (LATE STAGE): DOR/3TC/TDF
PRODUCT PROFILE (LATE STAGE): TIVICAY/EPIVIR
PRODUCT PROFILE (LATE STAGE): CABOTEGRAVIR/RILPIVIRINE
PRODUCT PROFILE (LATE STAGE): FOSTEMSAVIR

List of Figures
Figure 1: HIV - current and future market dynamics analysis
Figure 2: Assessment summary of key marketed and pipeline drugs for HIV
Figure 3: HIV total market value across the US and five major EU markets, by country, 2017-26
Figure 4: HIV total market value across the US and five major EU markets, by class, 2017-26
Figure 5: HIV sales in the US, 2017-26
Figure 6: HIV sales in the five major EU markets, by country, 2017-26
Figure 7: Sales of B/F/TAF compared to INSTI-based STRs and injections, by product, 2017-26
Figure 8: Sales of ViiV Healthcare’s oral two-drug regimens compared to B/F/TAF and Symtuza, by product, 2017-26
Figure 9: HIV sales across the US and five major EU markets, by company, 2017-26
Figure 10: The author’s HIV forecast methodology
Figure 11: Price sources and calculations, by country
Figure 12: Atripla for HIV - SWOT analysis
Figure 13: Drug assessment summary of Atripla for HIV
Figure 14: Drug assessment summary of Atripla for HIV
Figure 15: Atripla sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 16: B/F/TAF for HIV - SWOT analysis
Figure 17: Drug assessment summary of B/F/TAF for HIV
Figure 18: Drug assessment summary of B/F/TAF for HIV
Figure 19: B/F/TAF sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 20: Complera for HIV - SWOT analysis
Figure 21: Drug assessment summary of Complera for HIV
Figure 22: Drug assessment summary of Complera for HIV
Figure 23: Complera sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 24: DOR/3TC/TDF for HIV - SWOT analysis
Figure 25: Drug assessment summary of DOR/3TC/TDF for HIV
Figure 26: Drug assessment summary of DOR/3TC/TDF for HIV
Figure 27: DOR/3TC/TDF sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 28: Descovy for HIV - SWOT analysis
Figure 29: Drug assessment summary of Descovy for HIV
Figure 30: Drug assessment summary of Descovy for HIV
Figure 31: Descovy sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 32: Genvoya for HIV - SWOT analysis
Figure 33: Drug assessment summary of Genvoya for HIV
Figure 34: Drug assessment summary of Genvoya for HIV
Figure 35: Genvoya sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 36: Isentress for HIV - SWOT analysis
Figure 37: Drug assessment summary of Isentress for HIV
Figure 38: Drug assessment summary of Isentress for HIV
Figure 39: Isentress sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 40: Juluca for HIV - SWOT analysis
Figure 41: Drug assessment summary of Juluca for HIV
Figure 42: Drug assessment summary of Juluca for HIV
Figure 43: Juluca sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 44: Odefsey for HIV - SWOT analysis
Figure 45: Drug assessment summary of Odefsey for HIV
Figure 46: Drug assessment summary of Odefsey for HIV
Figure 47: Odefsey sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 48: Prezista franchise for HIV - SWOT analysis
Figure 49: Drug assessment summary of Prezista franchise for HIV
Figure 50: Drug assessment summary of Prezista franchise for HIV
Figure 51: Prezista sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 52: Prezcobix sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 53: Reyataz franchise for HIV - SWOT analysis
Figure 54: Drug assessment summary of Reyataz franchise for HIV
Figure 55: Drug assessment summary of Reyataz franchise for HIV
Figure 56: Reyataz sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 57: Evotaz sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 58: Stribild for HIV - SWOT analysis
Figure 59: Drug assessment summary of Stribild for HIV
Figure 60: Drug assessment summary of Stribild for HIV
Figure 61: Stribild sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 62: Symtuza for HIV - SWOT analysis
Figure 63: Drug assessment summary of Symtuza for HIV
Figure 64: Drug assessment summary of Symtuza for HIV
Figure 65: Symtuza sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 66: Tivicay for HIV - SWOT analysis
Figure 67: Drug assessment summary of Tivicay for HIV
Figure 68: Drug assessment summary of Tivicay for HIV
Figure 69: Tivicay sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 70: Tivicay/Epivir for HIV - SWOT analysis
Figure 71: Drug assessment summary of Tivicay/Epivir for HIV
Figure 72: Drug assessment summary of Tivicay/Epivir for HIV
Figure 73: Tivicay/Epivir sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 74: Triumeq for HIV - SWOT analysis
Figure 75: Drug assessment summary of Triumeq for HIV
Figure 76: Drug assessment summary of Triumeq for HIV
Figure 77: Triumeq sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 78: Truvada for HIV - SWOT analysis
Figure 79: Drug assessment summary of Truvada for HIV
Figure 80: Drug assessment summary of Truvada for HIV
Figure 81: Truvada sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 82: Cabotegravir/rilpivirine for HIV - SWOT analysis
Figure 83: Drug assessment summary of cabotegravir/rilpivirine for HIV
Figure 84: Drug assessment summary of cabotegravir/rilpivirine for HIV
Figure 85: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 86: Fostemsavir for HIV - SWOT analysis
Figure 87: Drug assessment summary of fostemsavir for HIV
Figure 88: Drug assessment summary of fostemsavir for HIV
Figure 89: Fostemsavir sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 90: Percentage of HIV prevalent population who are diagnosed and undiagnosed in the US and five major EU markets, by country
Figure 91: Percentage of the HIV-diagnosed population under physician care in the US and five major EU markets, by country
Figure 92: Breakdown of pharmacologically treated HIV patients in the US and five major EU markets, by line of therapy and country
Figure 93: Percentage of respondents in the US and five major EU markets who agree with initiating treatment in all patients, by country
Figure 94: Treatment status of HIV patients under physician care in the US and five major EU markets, by country
Figure 95: Top five brands used for the treatment of first-line HIV patients, by country
Figure 96: Top five regimens used for the treatment of first-line HIV patients, by country
Figure 97: Top five regimens used for the treatment of second-line HIV patients, by country
Figure 98: Top five brands used for the treatment of second-line HIV patients, by country
Figure 99: Top five regimens used for the treatment of third-line HIV patients, by country
Figure 100: Top five brands used for the treatment of third-line HIV patients, by country
Figure 101: Top five regimens used for the treatment of fourth-line and beyond HIV patients, by country
Figure 102: Top five brands used for the treatment of fourth-line and beyond HIV patients, by country
Figure 103: Relative importance of unmet needs in HIV treatment in the US and five major EU markets, by country
Figure 104: Physician views on potential adherence impact of breaking up FDCs in HIV in the US and five major EU markets, by country
Figure 105: Extent of physician comfort with breaking up FDCs to prescribe separate generic components in HIV in the US and five major EU markets, by country
Figure 106: Physician views on whether cost savings justify the breaking up of FDCs in HIV in the US and five major EU markets, by country
Figure 107: Trends in total prevalent cases of HIV in the US and five major EU markets, by country, 2016-36
Figure 108: Absolute change in total prevalent cases of HIV in the US and five major EU markets, by country, 2016-36
Figure 109: Proportion of total prevalent HIV cases, by gender and country, 2016
Figure 110: Diagnosis status of prevalent HIV cases, by country, 2016
Figure 111: Trends in diagnosed incident cases of HIV in the US, Japan, and five major EU markets, by country, 2016-36
Figure 112: Absolute change in diagnosed incident cases of HIV in the US, Japan, and five major EU markets, by country, 2016-36
Figure 113: Proportion of incident HIV cases, by transmission route and country, 2016
Figure 114: Diagnosed incident and total prevalent cases of HIV in the US and five major EU markets, by country, 2016
Figure 115: AIDS-related deaths by WHO region, 2000 and 2015
Figure 116: Atripla for HIV - SWOT analysis
Figure 117: Drug assessment summary of Atripla for HIV
Figure 118: Drug assessment summary of Atripla for HIV
Figure 119: Atripla sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 120: Complera for HIV - SWOT analysis
Figure 121: Drug assessment summary of Complera for HIV
Figure 122: Drug assessment summary of Complera for HIV
Figure 123: Complera sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 124: Descovy for HIV - SWOT analysis
Figure 125: Drug assessment summary of Descovy for HIV
Figure 126: Drug assessment summary of Descovy for HIV
Figure 127: Descovy sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 128: Genvoya for HIV - SWOT analysis
Figure 129: Drug assessment summary of Genvoya for HIV
Figure 130: Drug assessment summary of Genvoya for HIV
Figure 131: Genvoya sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 132: Isentress for HIV - SWOT analysis
Figure 133: Drug assessment summary of Isentress for HIV
Figure 134: Drug assessment summary of Isentress for HIV
Figure 135: Isentress sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 136: Juluca for HIV - SWOT analysis
Figure 137: Drug assessment summary of Juluca for HIV
Figure 138: Drug assessment summary of Juluca for HIV
Figure 139: Juluca sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 140: Odefsey for HIV - SWOT analysis
Figure 141: Drug assessment summary of Odefsey for HIV
Figure 142: Drug assessment summary of Odefsey for HIV
Figure 143: Odefsey sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 144: Prezista franchise for HIV - SWOT analysis
Figure 145: Drug assessment summary of Prezista franchise for HIV
Figure 146: Drug assessment summary of Prezista franchise for HIV
Figure 147: Prezista sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 148: Prezcobix sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 149: Reyataz franchise for HIV - SWOT analysis
Figure 150: Drug assessment summary of Reyataz franchise for HIV
Figure 151: Drug assessment summary of Reyataz franchise for HIV
Figure 152: Reyataz sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 153: Evotaz sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 154: Stribild for HIV - SWOT analysis
Figure 155: Drug assessment summary of Stribild for HIV
Figure 156: Drug assessment summary of Stribild for HIV
Figure 157: Stribild sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 158: Symtuza for HIV - SWOT analysis
Figure 159: Drug assessment summary of Symtuza for HIV
Figure 160: Drug assessment summary of Symtuza for HIV
Figure 161: Symtuza sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 162: Tivicay for HIV - SWOT analysis
Figure 163: Drug assessment summary of Tivicay for HIV
Figure 164: Drug assessment summary of Tivicay for HIV
Figure 165: Tivicay sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 166: Triumeq for HIV - SWOT analysis
Figure 167: Drug assessment summary of Triumeq for HIV
Figure 168: Drug assessment summary of Triumeq for HIV
Figure 169: Triumeq sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 170: Truvada for HIV - SWOT analysis
Figure 171: Drug assessment summary of Truvada for HIV
Figure 172: Drug assessment summary of Truvada for HIV
Figure 173: Truvada sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 174: B/F/TAF for HIV - SWOT analysis
Figure 175: Drug assessment summary of B/F/TAF for HIV
Figure 176: Drug assessment summary of B/F/TAF for HIV
Figure 177: B/F/TAF sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 178: DOR/3TC/TDF for HIV - SWOT analysis
Figure 179: Drug assessment summary of DOR/3TC/TDF for HIV
Figure 180: Drug assessment summary of DOR/3TC/TDF for HIV
Figure 181: DOR/3TC/TDF sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 182: Tivicay/Epivir for HIV - SWOT analysis
Figure 183: Drug assessment summary of Tivicay/Epivir for HIV
Figure 184: Drug assessment summary of Tivicay/Epivir for HIV
Figure 185: Tivicay/Epivir sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 186: Cabotegravir/rilpivirine for HIV - SWOT analysis
Figure 187: Drug assessment summary of cabotegravir/rilpivirine for HIV
Figure 188: Drug assessment summary of cabotegravir/rilpivirine for HIV
Figure 189: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country, 2017-26
Figure 190: Fostemsavir for HIV - SWOT analysis
Figure 191: Drug assessment summary of fostemsavir for HIV
Figure 192: Drug assessment summary of fostemsavir for HIV
Figure 193: Fostemsavir sales for HIV across the US and five major EU markets, by country, 2017-26

List of Tables
Table 1: HIV sales across the US and five major EU markets, by company ($m), 2017-26
Table 2: Molecules and brands included in the author’s patient-based HIV forecast
Table 3: Exchange rates used for calculating prices
Table 4: Infectious disease specialists surveyed for the HIV primary research study, 2017
Table 5: Atripla drug profile
Table 6: Atripla pivotal data in HIV
Table 7: Atripla sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 8: B/F/TAF drug profile
Table 9: B/F/TAF Phase III data in HIV
Table 10: B/F/TAF Phase III trials in HIV
Table 11: B/F/TAF sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 12: Complera drug profile
Table 13: Complera pivotal data in HIV
Table 14: Complera other late-phase trial data in HIV
Table 15: Complera sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 16: DOR/3TC/TDF drug profile
Table 17: DOR/3TC/TDF Phase III data in HIV
Table 18: DOR/3TC/TDF Phase III trials in HIV
Table 19: Doravirine Phase III trials in HIV
Table 20: DOR/3TC/TDF sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 21: Descovy drug profile
Table 22: Descovy pivotal data in HIV
Table 23: Descovy other late-phase trials in HIV
Table 24: Descovy sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 25: Genvoya drug profile
Table 26: Genvoya pivotal data in HIV
Table 27: Genvoya other late-phase data in HIV
Table 28: Genvoya ongoing late-phase trials in HIV
Table 29: Genvoya sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 30: Isentress drug profile
Table 31: Isentress pivotal data in HIV
Table 32: Isentress sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 33: Juluca drug profile
Table 34: Juluca Phase III data in HIV
Table 35: Juluca sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 36: Odefsey drug profile
Table 37: Odefsey pivotal data in HIV
Table 38: Odefsey other late-phase data in HIV
Table 39: Odefsey sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 40: Prezista drug profile
Table 41: Prezcobix drug profile
Table 42: Prezista pivotal data in HIV
Table 43: Prezista pivotal data in HIV
Table 44: Prezista sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 45: Prezcobix sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 46: Reyataz drug profile
Table 47: Evotaz drug profile
Table 48: Reyataz pivotal data in HIV
Table 49: Reyataz other late-phase data in HIV
Table 50: Reyataz other late-phase data in HIV
Table 51: Reyataz sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 52: Evotaz sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 53: Stribild drug profile
Table 54: Stribild pivotal data in HIV
Table 55: Stribild other late-phase data in HIV
Table 56: Stribild sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 57: Symtuza drug profile
Table 58: Symtuza pivotal data in HIV
Table 59: Symtuza sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 60: Tivicay drug profile
Table 61: Tivicay pivotal data in HIV
Table 62: Tivicay pivotal data in HIV
Table 63: Tivicay ongoing late-phase clinical trials in HIV
Table 64: Tivicay sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 65: Tivicay/Epivir drug profile
Table 66: Tivicay/Epivir Phase III trials in HIV
Table 67: Tivicay/Epivir Phase II data in HIV
Table 68: Tivicay/Epivir sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 69: Triumeq drug profile
Table 70: Triumeq pivotal data in HIV
Table 71: Triumeq other late-phase data in HIV
Table 72: Triumeq sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 73: Truvada drug profile
Table 74: Truvada pivotal data in HIV
Table 75: Truvada pivotal data in HIV
Table 76: Truvada sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 77: Cabotegravir/rilpivirine drug profile
Table 78: Cabotegravir/rilpivirine Phase III trials in HIV
Table 79: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 80: Fostemsavir drug profile
Table 81: Fostemsavir Phase III trial in HIV
Table 82: Fostemsavir Phase II data in HIV
Table 83: Fostemsavir sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 84: Infectious disease specialists surveyed for the HIV primary research study, 2017
Table 85: Therapies discussed in the HIV key opinion leader primary research study, 2017
Table 86: HIV total infections, new infections, and AIDS-attributable deaths, by region, 2016
Table 87: New HIV diagnoses in the US and five major EU markets, by transmission route, 2016
Table 88: Per-act HIV transmission risk, by transmission route
Table 89: CDC classification system for HIV-infected adults and adolescents
Table 90: Symptomatic conditions included in CDC HIV classification system clinical categories
Table 91: WHO clinical staging of HIV/AIDS for adults and adolescents
Table 92: Treatments available for HIV across the US and five major EU markets
Table 93: Summary of "recommended" treatment options in HHS and EACS treatment guidelines
Table 94: HIV prevalence, infections, and AIDS-attributable deaths in 2015, by region
Table 95: Sources used for the epidemiological analysis of HIV in the US, Japan, and five major EU markets, by country
Table 96: Data sources used to describe the diagnosed prevalent HIV population, by country
Table 97: Data sources used to segment diagnosed incident HIV cases by AIDS at diagnosis, by country
Table 98: Data sources used to segment diagnosed incident HIV cases by transmission category, by country
Table 99: Total prevalent cases of HIV in the US and five major EU markets, by country, 2016-36
Table 100: Gender-specific total prevalent cases of HIV in adults and children in the US and five major EU markets, by country, 2016
Table 101: Diagnosed and undiagnosed prevalent HIV cases, by country, 2016
Table 102: Co-morbid tuberculosis, bone impairments and renal impairments in adult diagnosed prevalent HIV cases, by country, 2016
Table 103: Diagnosed incident cases of HIV in the US, Japan, and five major EU markets, by country, 2016-36
Table 104: Gender-specific diagnosed incident cases of HIV in adults and children in the US, Japan, and five major EU markets, by country, 2016
Table 105: Diagnosed incident cases of HIV diagnosed at AIDS stage, in adults, in the US, Japan, and five major EU markets, by country, 2016
Table 106: Number and proportion of incident HIV cases, by transmission route, and country, 2016
Table 107: Factors contributing to the consideration of HIV as a chronic disease, by disease characteristic and time period
Table 108: PrEP availability, by country, 2017
Table 109: Validation of total prevalent and diagnosed incident HIV forecast estimates against benchmark estimates, by country
Table 110: Key marketed drugs for HIV
Table 111: Atripla drug profile
Table 112: Atripla pivotal data in HIV
Table 113: Atripla sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 114: Complera drug profile
Table 115: Complera pivotal data in HIV
Table 116: Complera other late-phase trial data in HIV
Table 117: Complera sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 118: Descovy drug profile
Table 119: Descovy pivotal data in HIV
Table 120: Descovy other late-phase trials in HIV
Table 121: Descovy sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 122: Genvoya drug profile
Table 123: Genvoya pivotal data in HIV
Table 124: Genvoya other late-phase data in HIV
Table 125: Genvoya ongoing late-phase trials in HIV
Table 126: Genvoya sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 127: Isentress drug profile
Table 128: Isentress pivotal data in HIV
Table 129: Isentress sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 130: Juluca drug profile
Table 131: Juluca Phase III data in HIV
Table 132: Juluca sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 133: Odefsey drug profile
Table 134: Odefsey pivotal data in HIV
Table 135: Odefsey other late-phase data in HIV
Table 136: Odefsey sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 137: Prezista drug profile
Table 138: Prezcobix drug profile
Table 139: Prezista pivotal data in HIV
Table 140: Prezista pivotal data in HIV
Table 141: Prezista sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 142: Prezcobix sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 143: Reyataz drug profile
Table 144: Evotaz drug profile
Table 145: Reyataz pivotal data in HIV
Table 146: Reyataz other late-phase data in HIV
Table 147: Reyataz other late-phase data in HIV
Table 148: Reyataz sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 149: Evotaz sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 150: Stribild drug profile
Table 151: Stribild pivotal data in HIV
Table 152: Stribild other late-phase data in HIV
Table 153: Stribild sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 154: Symtuza drug profile
Table 155: Symtuza pivotal data in HIV
Table 156: Symtuza sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 157: Tivicay drug profile
Table 158: Tivicay pivotal data in HIV
Table 159: Tivicay pivotal data in HIV
Table 160: Tivicay ongoing late-phase clinical trials in HIV
Table 161: Tivicay sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 162: Triumeq drug profile
Table 163: Triumeq pivotal data in HIV
Table 164: Triumeq other late-phase data in HIV
Table 165: Triumeq sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 166: Truvada drug profile
Table 167: Truvada pivotal data in HIV
Table 168: Truvada pivotal data in HIV
Table 169: Truvada sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 170: Key Phase III pipeline products in development for HIV
Table 171: B/F/TAF drug profile
Table 172: B/F/TAF Phase III data in HIV
Table 173: B/F/TAF Phase III trials in HIV
Table 174: B/F/TAF sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 175: DOR/3TC/TDF drug profile
Table 176: DOR/3TC/TDF Phase III data in HIV
Table 177: DOR/3TC/TDF Phase III trials in HIV
Table 178: Doravirine Phase III trials in HIV
Table 179: DOR/3TC/TDF sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 180: Tivicay/Epivir drug profile
Table 181: Tivicay/Epivir Phase III trials in HIV
Table 182: Tivicay/Epivir Phase II data in HIV
Table 183: Tivicay/Epivir sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 184: Cabotegravir/rilpivirine drug profile
Table 185: Cabotegravir/rilpivirine Phase III trials in HIV
Table 186: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Table 187: Fostemsavir drug profile
Table 188: Fostemsavir Phase III trial in HIV
Table 189: Fostemsavir Phase II data in HIV
Table 190: Fostemsavir sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll